- Home
- HSLV vs CSTL Comparison
HSLV vs CSTL Comparison
Compare HSLV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSLV | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | 13 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.6M | 806.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HSLV | CSTL |
|---|---|---|
| Price | $5.93 | $24.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $47.17 |
| AVG Volume (30 Days) | ★ 269.7K | 254.4K |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | $50.42 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $4.72 | $14.59 |
| 52 Week High | $6.52 | $44.28 |
Technical Indicators
Market Signals| Indicator | HSLV | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 38.24 |
| Support Level | $4.87 | $24.89 |
| Resistance Level | $6.10 | $26.19 |
| Average True Range (ATR) | 0.49 | 0.95 |
| MACD | 0.08 | 0.32 |
| Stochastic Oscillator | 81.63 | 56.61 |
Price Performance
Historical ComparisonAbout HSLV Highlander Silver Corp. Common Shares
Highlander Silver Corp. is a mineral exploration company focused on the discovery of silver-gold-polymetallic projects in the Central Andes. The Company is focused on developing the La Estrella project in central Peru. The Company's San Luis gold-silver project is located in the Ancash Department of central Peru with the mining concessions covering approximately 230 square kilometers.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.